Patents by Inventor Yingjie Lu
Yingjie Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981708Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.Type: GrantFiled: July 31, 2020Date of Patent: May 14, 2024Assignee: Children's Medical Center CorporationInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Patent number: 11976097Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: GrantFiled: October 13, 2022Date of Patent: May 7, 2024Assignee: Children's Medical Center CorporationInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Publication number: 20240025952Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: ApplicationFiled: October 13, 2022Publication date: January 25, 2024Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Publication number: 20230390375Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: ApplicationFiled: May 26, 2023Publication date: December 7, 2023Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
-
Patent number: 11701416Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: GrantFiled: April 22, 2021Date of Patent: July 18, 2023Assignee: Affinivax, Inc.Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
-
Publication number: 20230089151Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: ApplicationFiled: September 16, 2022Publication date: March 23, 2023Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard MALLEY, Yingjie LU, Fan ZHANG
-
Publication number: 20230091255Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: ApplicationFiled: September 9, 2022Publication date: March 23, 2023Inventors: Gilles R. Besin, Teresa J. Broering, Heidi Burke, Yingjie Lu, Richard Malley, Janet E. McCombs, Velupillai Puvanesarajah, Shite Sebastian, Onkar Sharma, Taylor C. Stevenson, Gang Yao, Fan Zhang
-
Publication number: 20230081705Abstract: The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal.Type: ApplicationFiled: June 7, 2022Publication date: March 16, 2023Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard MALLEY, Yingjie LU, Fan ZHANG
-
Patent number: 11576958Abstract: The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal.Type: GrantFiled: February 7, 2014Date of Patent: February 14, 2023Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Patent number: 11560410Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: GrantFiled: February 10, 2020Date of Patent: January 24, 2023Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Publication number: 20220378895Abstract: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.Type: ApplicationFiled: January 7, 2022Publication date: December 1, 2022Applicant: Children's Medical Center CorporationInventors: Richard Malley, Yingjie Lu, Kristin L. Moffitt
-
Publication number: 20220362367Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.Type: ApplicationFiled: March 7, 2022Publication date: November 17, 2022Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard MALLEY, Fan ZHANG, Yingjie LU
-
Patent number: 11305001Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.Type: GrantFiled: March 28, 2018Date of Patent: April 19, 2022Assignee: The Children's Medical Center CorporationInventors: Richard Malley, Fan Zhang, Yingjie Lu
-
Patent number: 11235047Abstract: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.Type: GrantFiled: June 28, 2016Date of Patent: February 1, 2022Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Kristin L. Moffitt
-
Publication number: 20210346487Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: ApplicationFiled: April 22, 2021Publication date: November 11, 2021Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
-
Publication number: 20210332090Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.Type: ApplicationFiled: July 31, 2020Publication date: October 28, 2021Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard MALLEY, Yingjie LU, Fan ZHANG
-
Patent number: 11013793Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: GrantFiled: September 12, 2019Date of Patent: May 25, 2021Assignee: Affinivax, Inc.Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
-
Publication number: 20210008192Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.Type: ApplicationFiled: March 28, 2018Publication date: January 14, 2021Applicant: The Children's Medical Center CorporationInventors: Richard MALLEY, Fan ZHANG, Yingjie LU
-
Publication number: 20200407404Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: ApplicationFiled: February 10, 2020Publication date: December 31, 2020Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Patent number: 10766932Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.Type: GrantFiled: May 11, 2012Date of Patent: September 8, 2020Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang